Physician profile
Brian M Bothe
NPI 1891792859
$998.69
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $96.54 · 2021: $184.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $267.51 | 2019-2021 | |
| Indivior INC. | $176.99 | 2019-2021 | |
| Daiichi Sankyo INC. | $101.66 | 2019 | |
| Abbvie INC. | $100.00 | 2021 | |
| Amgen INC. | $91.47 | 2019 | |
| Biodelivery Sciences International, INC. | $75.39 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $68.88 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $27.48 | 2019-2020 | |
| Alkermes, INC. | $25.75 | 2021 | |
| Shionogi INC | $24.14 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.29 | 2019 | |
| Gilead Sciences, INC. | $14.03 | 2019 | |
| Pfizer INC. | $11.10 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Bothe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.